



26 April 2010
EMA/CVMP/257821/2010
Veterinary Medicines and Product Data Management

Committee for Medicinal Products for Veterinary Use

Monthly report of application procedures, guidelines and related documents

April 2010

The CVMP Monthly Report includes statistical data for the current and previous two years on Scientific Advice, Initial Evaluations, Variations, Line Extensions, Renewals, MRLs Initial Evaluations and MRLs Extensions/Modifications and Arbitration and Referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted Guidelines and other public documents.

Applications for Medicinal Products for Veterinary Use and Maximum Residue Limits (MRLs)

| Scientific Advice Requests | | | | | |
|----------------------------|-------|------|------|------|-------|
| | 95-07 | 2008 | 2009 | 2010 | Total |
| Submitted | 58 | 5 | 11 | 10 | 84 |

| Initial Evaluation | | | | | |
|--------------------------------|-------|------|------|------|-------|
| | 95-07 | 2008 | 2009 | 2010 | Total |
| Full (Submitted) | 97 | 13 | 14 | 6 | 130 |
| Abridged/ Generics (Submitted) | 7 | 3 | 1 | 1 | 12 |
| Withdrawals | 11 | 1 | 0 | 0 | 12 |
| Positive Opinions | 78 | 13 | 13 | 0 | 104 |
| Negative Opinions | 1 | 0 | 0 | 0 | 1 |

| Marketing Authorisations | | | | | |
|--------------------------|-------|------|------|------|-------|
| | 95-07 | 2008 | 2009 | 2010 | Total |
| Granted | 75 | 13 | 12 | 4 | 104 |
| Withdrawals | 1 | 1 | 0 | 3 | 5 |
| Not renewed | 2 | 0 | 0 | 0 | 2 |

| Extensions - Annex II Applications | | | | | |
|------------------------------------|-------|------|------|------|-------|
| | 95-07 | 2008 | 2009 | 2010 | Total |
| Submitted | 56 | 4 | 12 | 0 | 72 |
| Withdrawals | 1 | 1 | 1 | 1 | 4 |
| Positive Opinions | 33 | 7 | 7 | 4 | 51 |
| Negative Opinions | 0 | 0 | 0 | 0 | 0 |



| Variations – Applications submitted | | | | | |
|--|-------|------|------|------|-------|
| | 95-07 | 2008 | 2009 | 2010 | Total |
| Type IA | 291 | 23 | 32 | 28 | 460 |
| Type IB | | 25 | 41 | 20 | |
| Type II | 158 | 52 | 40 | 7 | 257 |
| Transfers | 9 | 2 | 3 | 0 | 14 |

| Renewals | | | | | |
|-------------------|-------|------|------|------|-------|
| | 95-07 | 2008 | 2009 | 2010 | Total |
| Submitted | 43 | 7 | 18 | 5 | 73 |
| Positive Opinions | 40 | 8 | 15 | 4 | 67 |
| Negative Opinions | 0 | 0 | 0 | 0 | 0 |

| Arbitrations and Community Referrals | | | | | |
|---|-------|------|------|------|-------|
| | 95-07 | 2008 | 2009 | 2010 | Total |
| Referrals Submitted | 27 | 11 | 9 | 1 | 48 |
| Opinions Reached | 14 | 6 | 14 | 4 | 38 |

| Establishment of MRLs for new substances | | | | | |
|---|-------|------|------|------|-------|
| | 95-07 | 2008 | 2009 | 2010 | Total |
| Submitted | 65 | 1 | 4 | 2 | 72 |
| Withdrawals | 5 | 0 | 0 | 0 | 5 |
| Positive Opinions ¹ | 52 | 2 | 2 | 0 | 56 |
| Negative Opinions ² | 6 | 1 | 0 | 0 | 7 |

| Extensions / Modifications/Extrapolations of MRLs | | | | | |
|--|-------|------|------|------|-------|
| | 95-07 | 2008 | 2009 | 2010 | Total |
| Submitted | 96 | 2 | 2 | 0 | 100 |
| Withdrawals | 4 | 0 | 0 | 0 | 4 |
| Positive Opinions ³ | 111 | 2 | 3 | 0 | 116 |
| Negative Opinions ⁴ | 6 | 0 | 0 | 0 | 6 |
| Extrapolations | 45 | 5 | 0 | 0 | 50 |

¹ Including opinions recommending definitive MRLs for substances with previously provisional maximum residue limits

² Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

Arbitrations and Community Referrals in 2010

| Type of referral | Date of clock start / CVMP opinion | <ul style="list-style-type: none"> ▪ Product name ▪ INN |
|---|--|---|
| Referral under Art. 35 of Directive 2001/82/EC | 11/02/2009 10/02/2010 | <ul style="list-style-type: none"> ▪ All strengths of water soluble powders and oral solutions containing doxycycline hyclate ▪ Doxycycline hyclate |
| Referral under Art. 35 of Directive 2001/82/EC | 16/04/2009 10/02/2010 | <ul style="list-style-type: none"> ▪ Veterinary medicinal formulations containing colistin at 2 MIU/ml and intended for administration in drinking water to any food producing species ▪ Colistin sulfate |
| Referral under Art. 35 of Directive 2001/82/EC | 13/05/2009 10/03/2010 (after re-examination) | <ul style="list-style-type: none"> ▪ Veterinary medicinal products containing quinolones or fluoroquinolones for all food-producing species ▪ Quinolones / fluoroquinolones |
| Referral under Art. 33(4) of Directive 2001/82/EC | 12/11/2008 11/11/2009 (after re-examination) | <ul style="list-style-type: none"> ▪ Tildren 500 mg ▪ Tiludronic acid (as disodium salt) |
| Referral under Art. 6(12) of Regulation (EC) No 1084/2003 | 14/10/2009 | <ul style="list-style-type: none"> ▪ Porcilis PRRS ▪ Live attenuated PRRS virus strain DV |
| Referral under Art. 6(12) of Regulation (EC) No 1084/2003 | 14/10/2009 | <ul style="list-style-type: none"> ▪ Porcilis M Hyo ▪ Inactivated whole cell concentrate of Mycoplasma hyopneumoniae strain 11 |
| Referral under Art. 34 of Directive 2001/82/EC | 11/11/2009 | <ul style="list-style-type: none"> ▪ Fortekor vet and associated names ▪ Benazepril hydrochloride |
| Referral under Art. 34 of Directive 2001/82/EC | 15/10/2008 10/03/2010 | <ul style="list-style-type: none"> ▪ Tiamutin premix ▪ Tiamulin fumarate |
| Referral under Art. 34 of Directive 2001/82/EC | 14/04/2010 | <ul style="list-style-type: none"> ▪ Synulox Lactating Cow and associated names ▪ Amoxicillin, clavulanic acid, prednisolone |

Guidelines and Working Documents in 2010

CVMP Environmental Risk Assessment (ERA)

| Reference number | Document title | Status |
|---------------------------------------|---|--|
| EMA/CVMP/ERA/430327/2009-CONSULTATION | Guideline on degradation of veterinary medicinal products in manure | Adopted for consultation, February 2010 (End of consultation, 31 August 2010) |

CVMP Immunologicals

| Reference number | Document title | Status |
|--------------------------------|---|------------------------|
| EMA/CVMP/IWP/58879/2010 | Reflection paper on data requirements for swine influenza vaccines against pandemic (H1N1) 2009 influenza | Adopted, February 2010 |
| EMA/CVMP/IWP/105506/2007 | Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), Bluetongue (BT) and Foot-and-Mouth disease (FMD) | Adopted, March 2010 |
| EMA/CVMP/IWP/43283/2010 | Recommendation on the submission of multi-strain dossier applications for vaccines against avian influenza (AI), Bluetongue (BT) and Foot-and-Mouth disease (FMD) | Adopted, March 2010 |
| EMA/CVMP/IWP/250147/2008 | Guideline on data requirements to support in-use stability claims for veterinary vaccines | Adopted, March 2010 |
| EMA/CVMP/IWP/582970/2009 | Reflection paper on control of the active substance in the finished product for immunological veterinary medicinal products (IVMPs) | Adopted, March 2010 |
| EMA/CVMP/IWP/439467/2007 | Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals | Adopted, March 2010 |
| EMA/CVMP/IWP/123243/2006-Rev.2 | Guideline on data requirements for immunological veterinary medicinal products intended for Minor Use or Minor Species/ Limited markets | Adopted, April 2010 |

CVMP Pharmacovigilance

| Reference number | Document title | Status |
|----------------------------|---|------------------------|
| EMA/CVMP/PhVWP/729768/2009 | Veterinary Pharmacovigilance 2009 Public Bulletin | Adopted, February 2010 |

Joint CHMP/CVMP Quality

| Reference number | Document title | Status |
|-------------------------------|---|---|
| EMA/CHMP/CVMP/QWP/809114/2009 | Concept paper on the revision of the guideline on process validation | Adopted for consultation, January 2010 (End of consultation, April 2010) |
| EMA/63033/2010 | Concept Paper on the need for revision of the guideline on stability testing for applications for variations to a marketing authorisation | Adopted for consultation, February 2010 (End of consultation, 30 April 2010) |
| EMA/CHMP/CVMP/QWP/80386/2010 | Questions and Answers concerning stability issues of pharmaceutical bulk products used in the manufacture of drug products | Adopted, February 2010 |

CVMP Safety

| Reference number | Document title | Status |
|---------------------------|---|---------------------|
| EMA/CVMP/SWP/543/03-Rev.1 | Guideline on user safety for pharmaceutical veterinary medicinal products | Adopted, March 2010 |

General

| Reference number | Document title | Status |
|--------------------------|--|------------------------|
| SOP/EMA/85634/2006-Rev.1 | Standard Operating Procedure (SOP) on Evaluation procedure for applications and requests for the establishment of Maximum Residue Limits (MRLs) under Articles 3, 9, 10 and 15 of Regulation (EC) 470/2009 | Adopted, February 2010 |